Exhibit 1
AGREEMENT
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of them of a statement on Schedule 13D (including amendments thereto) with respect to the shares of common stock, par value $0.0001 per share, of Dermata Therapeutics, Inc. a Delaware corporation, and further agree that this Joint Filing Agreement be included as Exhibit 1 to such Schedule 13D. In evidence thereof, the undersigned hereby execute this agreement this 27th day of August, 2021.
| August 27, 2021 | ||
| By: | /s/ David Hale |
David Hale
| HALE BIOPHARMA VENTURES LLC | ||
| By: David Hale, its Chief Executive Officer | ||
| By: | /s/ David Hale |
| Name: | David Hale | |||
| Title: | Chief Executive Officer | |||
